May 30, 2020 R&D Center finished 3 patents related to RNAi treatment
April 20, 2019 R&D Center finished the pharmacological test of NAMPT inhibitor for pancreatic cancer
April 25, 2018 R&D Center finished the preparation of an enzyme-catalyzedchiral amino acid
November 22, 2017 R&D Center finished the development of a new intermediate of one sleep disorders drug
April 25,2017 R&D Center finished the manufacture procedure of one Diabetes drug
Fabruary 28, 2017 R&D Center successfully applied enzyme technology to chemical drug production
December 8, 2016 R&D Center finished the lab procedure of one Epilepsy drug
December 5, 2016 R&D Center finished the lab procedure of one sleep disorders drug
November 21, 2016 R&D Center finished the lab procedure of one multiple Myeloma drug
October 17, 2016 RPC finished the lab procedure of one long acting β2-agonist
September 21, 2016 R&D Center finished the preparations of two kinds of fluorescent biological probes
July 24, 2016 R&D Center finished the lab procedure of one gout treatment drug
July 8, 2016 R&D Center finished the pilot production of one sugar compound
June 21, 2016 The company participated in Shanghai CPhI 2016
May 30, 2016 R&D Center got a break-through in production process of one sugar compound
May 18, 2016 R&D Center finished the lab procedure of one cancer drug
April 6, 2016 R&D Center finished the lab procedure of three APIs for treating HCV
January 15, 2016 RPC finished three APIs for HCV small scale process
January 4, 2016 RPC finished one LABA small scale process
December 2, 2015 Life material section obtained a patent of polymer preparation
November 30, 2015 RPP completed sustain released tablet project small scale process, prepare for declaration
November 27, 2015 R&D’s staff obtained the qualifications of CMA /Laboratory Accreditation internal auditor
November 15, 2015 Company was award as “eagle plan” enterprise by RPP’s projects
November 3, 2015 Company was award as “Hangzhou high-tech enterprises” by R&D’s projects
October 31, 2015 RPC finished one orexin receptor antagonist small scale process
October 12, 2015 Life material section completed one polymer small scale process, prepare for pilot scale
September 11, 2015 Enzyme catalysis section got a break-through in polysaccharide purification process
June 26, 2015 The company carries RPC’s molecules to participate in Shanghai CPHI, officially entered the international market
April 10, 2015 Estabished Pharmaceutical Division, including pharmaceutical chemistry section (RPC) on and pharmaceutics section (RPP).
February 28, 2015 Obtained a patent of excipients
November 14, 2014 Yewei Yang, Head of Customer Order Division,Industry Centerl approved IATA Air Transport certification qualifications
June 23, 2014 Accept Merck Schuchardt OHG Group on supplier qualification and chemical sampling qualified on-site audit
February 11, 2014 Signed a cooperation agreement with Hangzhou Minsheng Institute
October 11, 2013 Signed a letter of intent with Mingsheng Pharmaceutical Co., Ltd.
September 30, 2013 Slow release of functional foods patent application
September 27, 2013 The company's two major applications for invention patents BSAZ823
September 5, 2013 The second batch of utility model patents into the application stage
August 23, 2013 The first patent for utility model into the application stage
June 27, 2013  Obtained the "hazardous chemicals business license"